Skip to search boxSkip to navigationSkip to main content

A Phase 4, Open-Label, Non-Randomized, Multicenter Study to Evaluate Efficacy (and Safety) of Intravenous Administration of Optison for Contrast-Enhanced Echocardiography in Pediatric Patients

  • Arash Sabati(corresponding author)
    ,
  • Shuo Wang
    ,
  • ,
  • Joshua Hawley
    ,
  • David Thompson
    ,
  • Francine Erenberg
*Corresponding author for this work
  • Phoenix Children's Hospital
    ,
  • Children's Hospital Los Angeles
    ,
  • ,
  • GE Healthcare
    ,
  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
    ,
  • Johns Hopkins University
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Contrast-enhanced echocardiography (CE-echo) is commonly used in adult patients to optimize endocardial border delineation (EBD) but there is limited experience in children. A prospective, open-label, non-randomized, multicenter study was performed to evaluate the efficacy of intravenous Optison for CE-echo in pediatric patients and determine the optimal dose of Optison. Subjects ≥ 9 and < 18 years with suboptimal echocardiograms (defined as ≥ 2 contiguous segments that could not be adequately visualized) were enrolled. After a baseline non-contrast echocardiogram (NC-echo), CE-echo was performed with 2 dose levels of Optison based on patient weight. The primary endpoint was visualization of the LV wall segments (LVWS) in apical 2- and 4-chamber views. An EBD score was calculated by assigning a value from 0 (no visualization) to 3 (optimal visualization) for 12 LVWS. 37 subjects across 8 sites completed the study. 30 had complete echocardiograms at both dose levels. 2 patients had usable images at dose 2 only. Mean age was 13.4 years (± 2.6) with 23 males (62%). Mean weight was 73.9 kg (± 36.8) with wide distribution of weight (interquartile range of 42–102 kg). There were 8 patients under 40 kg. Most subjects had a prior medical/surgical history (n = 33, 89%). Both dose levels of Optison CE-echo improved the number of LVWS visualized from 3.7 ± 1.1 on NC-echo to 10.0 ± 0.1 with dose 1 (p < 0.001) and 10.5 ± 0.1 with dose 2 (p < 0.001). EBD score also improved at both dose levels from 11.9 ± 2.5 for NC-echo to 28.5 ± 1.7 for dose 1 (p < 0.001) and 30.2 ± 8.4 for dose 2 (p < 0.001). The number of suboptimal echocardiograms improved from 92.3% ± 10.7 in NC-echo to 26.2% ± 9 with dose 1 (p < 0.001) and 30.8% ± 4.5 with dose 2 (p < 0.001). CE-echo with intravenous Optison in pediatric patients improved the number of LVWS visualized, improved EBD score, and reduced the number of suboptimal echocardiograms at both dosages used in this study. Intravenous Optison can improve LV visualization in pediatric patients with suboptimal echocardiograms.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 2052-2066 (15 pages)

Journal (Volume, Issue Number)

Pediatric Cardiology (Volume 47, Issue 5)

Publication milestones

  • Accepted/In press - 2025
  • Published - 06/2026

Publication status

Published - 06/2026

ISSN

0172-0643

Publication IDs

  • Scopus: 105014255936
  • PubMed: 40866633

Publication metrics

Metrics

Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Usage
11
Captures
1

Funding Details

Funding for this study was provided by GE Healthcare who was involved in study design, data collection and data analysis. Writing of this report and decision to submit was carried out by the study authors who also served as principal investigators at their site. GE Healthcare was allowed to review the written report prior to submission.
FunderFunding numbers
GE Healthcare
-